Weight Loss$155–$225

BAM-15: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 6 sources cited

Overview

BAM-15 is a next-generation mitochondrial uncoupling agent that dissipates the proton gradient across the inner mitochondrial membrane, converting stored energy directly into heat rather than ATP. Unlike the notorious uncoupler DNP (2,4-dinitrophenol), BAM-15 selectively targets mitochondrial membranes without depolarizing the plasma membrane, providing a dramatically wider therapeutic window. In mice, it decreases body fat mass, improves insulin sensitivity and lowers liver fat, without affecting food intake, lean mass or body temperature. In a mouse model of steatohepatitis it reduced liver fat but did not change fibrosis.

Mechanism of Action

BAM-15 functions as a protonophore, a molecule that shuttles protons across biological membranes. It selectively inserts into the inner mitochondrial membrane and facilitates the passage of protons from the intermembrane space back into the mitochondrial matrix, bypassing ATP synthase (Complex V). This short-circuits oxidative phosphorylation — the proton-motive force is dissipated as heat rather than being used to generate ATP. The cell responds to this ATP deficit by increasing substrate oxidation — burning more fats and sugars to regenerate the proton gradient. This creates a futile cycle that elevates metabolic rate and energy expenditure without physical activity. BAM-15 also activates AMPK downstream (sensing the reduced ATP/AMP ratio), which further promotes fatty acid oxidation, glucose uptake, and mitochondrial biogenesis. The critical safety distinction from DNP is membrane selectivity. DNP is a non-selective protonophore that depolarizes both mitochondrial and plasma membranes, disrupting cellular ion gradients and causing dangerous hyperthermia with a narrow margin between effective and lethal doses. BAM-15 was identified precisely because it uncouples mitochondria without depolarizing the plasma membrane, and it is less cytotoxic in cultured cells than FCCP, an uncoupler of equal potency. Additionally, it reduces reactive oxygen species (ROS) production by keeping the electron transport chain in a more oxidized state, providing antioxidant benefits.

BAM-15 Benefits: What the Research Shows

  • A 2020 study published in Nature Communications demonstrated BAM-15 decreased body fat mass in diet-induced obese mice without affecting food intake, lean body mass, core body temperature, or biochemical and haematological markers of toxicity — addressing DNP's primary safety concern.
  • The same study showed BAM-15 improved insulin sensitivity in multiple tissue types in hyperinsulinaemic euglycaemic clamp studies, suggesting direct metabolic benefits on skeletal muscle and liver.
  • In that study BAM-15 did not alter biochemical or haematological markers of toxicity at the doses used, but no formal therapeutic window for BAM-15 has been published.
  • BAM-15 decreased liver fat and inflammatory lipids in diet-induced obese mice, and in a separate mouse model of steatohepatitis it reduced liver fat, though no treatment in that study changed liver fibrosis.
  • Mitochondrial selectivity confirmed: BAM-15 uncouples mitochondria without depolarizing the plasma membrane, and is less cytotoxic than FCCP in cultured cells.
  • Reduced reactive oxygen species (ROS) production in treated tissues, suggesting antioxidant-like benefits alongside metabolic enhancement.
  • BAM-15 dose-dependently protected mice from acute renal ischaemia-reperfusion injury, indicating tissue-protective effects beyond fat loss.

BAM-15 Dosage

  • Oral liquid formulation: typically supplied at 30–50 mg/mL. Standard dose is 0.5–1 mL daily (15–50 mg depending on concentration and individual response).
  • Research dose in mice: 10 mg/kg/day orally. The published mouse study reported decreased body fat mass with no change in toxicity markers.
  • Human-equivalent dose estimation: approximately 0.8–1.5 mg/kg/day based on allometric scaling from murine data. Start conservatively.
  • Dose titration recommended: begin with half the target dose for 1–2 weeks to assess tolerance before increasing. Monitor subjective body temperature and energy levels.
  • Take with food to improve oral absorption and reduce GI side effects. Morning dosing is preferred to align with daytime metabolic activity.
  • Cycle: 8–12 weeks on, 4 weeks off. Monitor body composition, fasting glucose, and liver enzymes.
  • Can be combined with SLU-PP-332 for complementary metabolic effects (mitochondrial uncoupling + exercise mimetic). Some vendors offer pre-made BAM-SLU blends.
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

BAM-15 Side Effects & Safety

Known Side Effects

  • Mild increase in body temperature — most users report feeling slightly warmer, particularly during the first week. Unlike DNP, this does not progress to dangerous hyperthermia at recommended doses.
  • Gastrointestinal discomfort — nausea, loose stools, or mild cramping, especially when taken on an empty stomach. Taking with food mitigates this.
  • Increased sweating — consistent with elevated metabolic rate and thermogenesis. Stay well-hydrated.
  • Fatigue during initial adaptation — the shift in cellular energetics can cause temporary tiredness as the body adjusts to reduced ATP efficiency. Usually resolves within 5–7 days.
  • Theoretical concern of reduced exercise performance at very high doses — if too much proton gradient is dissipated, ATP production during intense exercise could be impaired. Stay within recommended doses.
  • Long-term human safety data does not exist — all safety data is preclinical. Proceed with appropriate caution.

Safety Profile

BAM-15 represents a major safety improvement over historical mitochondrial uncouplers. Unlike DNP, it uncouples mitochondria without depolarizing the plasma membrane, which is what gave it a wider margin in cell work. In the mouse obesity study, body temperature and biochemical and haematological markers of toxicity were unchanged at the doses used. No dose margin over the effective dose has been published, and no safety margin in people is known. However, all safety data is preclinical. No human clinical trials have been conducted, and the long-term effects of sustained mitochondrial uncoupling in humans are unknown. Contraindications include mitochondrial diseases, cardiac arrhythmias, hyperthyroidism (already elevated metabolic rate), and pregnancy/breastfeeding. Individuals taking medications that affect mitochondrial function (metformin, statins) should exercise caution. Monitoring liver enzymes, thyroid function, and fasting glucose during use is prudent.

What to Expect

Days 1–5: Slight increase in body temperature and warmth, particularly after dosing. Energy levels may fluctuate as cells adjust to altered energetics. GI effects are most likely during this adaptation period. Weeks 1–2: Metabolic adaptation stabilizes. Energy returns to normal or improves. Increased sweating during activity. Subtle fat loss may begin, particularly noticeable in morning appearance before eating. Weeks 3–6: Primary fat loss window. Body composition changes become visible — reduced abdominal fat, improved definition. Appetite remains stable (not suppressed). Improved glucose and insulin markers may be detectable on blood work. Weeks 7–12: Continued fat loss with gradual plateau. Liver function improvements (reduced hepatic fat) may be reflected in ALT/AST normalization. Total fat mass reduction of 10–15% is achievable with concurrent exercise and dietary awareness.

Common Stacks

Storage & Handling

Oral liquid formulations: Store at room temperature (59–86°F / 15–30°C) in a cool, dark place. Protect from direct sunlight. Shelf life is typically 6–12 months from manufacture. Shake well before each use. Do not refrigerate unless specified by the manufacturer, as some formulations may precipitate at cold temperatures.

Pricing & Available Variants

$155 – $225price range
30mg/ML 30ML50mg/ML 30ML

Prices sourced from peptides.gg marketplace. Prices may vary.

References

Related Peptides

Track BAM-15 in Your Protocol

Log your BAM-15 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free